What, if anything, is controversial about calcium antagonists?

American Journal of Hypertension

Volumn 9, Issue 12 SUPPL. 1, 1996, Pages

  Messerli, Franz H ^a  

^a NONE

Author keywords

Calcium antagonists; Coronary artery disease; Drug therapy; Hypertension; Myocardial infarction

Indexed keywords

AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; FELODIPINE; NIFEDIPINE; NISOLDIPINE; NITRENDIPINE; VERAPAMIL;

ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAM; HEART INFARCTION; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; PRIORITY JOURNAL; SURVIVAL;

CALCIUM CHANNEL BLOCKERS; CORONARY DISEASE; HUMANS; HYPERTENSION; MYOCARDIAL INFARCTION;

EID: 0030460949     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(96)00387-1     Document Type: Article

References (24)

1. Psaty BM, Heckbert SR, Koepsell TD, et al: The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620-625.
2. Furberg CD, Psaty BM, Meyer J: Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326-1331.
3. Pahor M, Guralnik JM, Corti MC, et al: Long-term survival and use of antihypertensive medications in older persons. J Am Geriat Soc 1995;43:1191-1197.
4. Messerli FH: Calcium channel blockers in antihypertensive therapy, in Proceedings of a Round Table Discussion: Calcium Antagonists: Which to Use, When, and How. New York, Lawrence Della Corte Publications, Inc., 1996, pp 9-13.
5. Wilson DC, Schwarts GL, Textor SC, Zachariah PK, Sheps SG: Precipitous fall in blood pressure in the treatment of chronic hypertension. Presented at the 5th International Symposium on Calcium Antagonists: Pharmacology and Clinical Research, Houston, Texas, September, 1991.
6. Psaty BM: On record, US Food and Drug Administration hearing, Bethesda, Maryland, January 25, 1996.
7. Opie LH, Messerli FH: Nifedipine and mortality: grave defects in the dossier. Circulation 1995;92:1068-1073.
8. Messerli FH: Are calcium antagonists safe (letter)? Lancet 1995;346:767-768.
9. Messerli FH: Case-control study, meta-analysis, and bouillabaisse: putting the calcium antagonist scare into context. Ann Intern Med 1995;123:888-889.
10. Held PH, Yusul S, Furberg CD: Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. Br Med J 1989;299:1187-1192.
11. Yusuf S, Held P, Furberg C: Update of effects of calcium antagonists in myocardial infarction or angina in light of the Second Danish Verapamil Infarction Trial (DAVIT II) and other recent studies. Am J Cardiol 1991; 67:1295-1297.
12. Lichtlen PR, Hugenholtz PG, Raffenbeul W, et al, on behalf of the INTACT group: Retardation of angiographic progression of coronary artery disease by nifedipine: results of International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). Lancet 1990; 335:1109-1113.
13. Gonser M, Vetter K, Noack F: Meta-analyses of interventional trials done in populations with different risks (letter). Lancet 1995;345:1304.
14. Messerh FH: Cardioprotection - not all calcium Antagonists are created equal. Am J Cardiol 1990;66(10) :855-856.
15. Messerli FH, Kowey P, Grodzicki T: Sublingual nifedipine for hypertensive emergencies (letter). Lancet 1991; 338:881.
16. Grossman E, Messerli FH, Grodzicki T, Kowey P: Should a moratorium be placed on nifedipine capsules in hypertension? JAMA 1996;276:328-331.
17. Packer M, O'Connor CM, Ghali JK, et al, for the Prospective Randomized Amlodipine Survival Evaluation Study Group: Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996;335:1107-1114.
18. Conn JN, Ziesche SM, Loss LE, Anderson GF, and the V-HeFT Study Group: Effect of felodipine on short-term exercise and neurohormones and long-term more tality in heart failure: results of V-HeFT III. Circulation 1990;82:1940-1953.
19. The DEFIANT-II Research Group: Doppler Flow and Echocardiography in Functional Cardiac Insufficiency: Assessment of Nisoldipine Therapy: results of the DEFIANT-II Study. Eur Heart J (in press).
20. Rehnqvist NJ, Hjemdahl P, Billing E, et al: Effects of metoprolol versus verapamil in patients with stable angina pectoris: the angina prognosis study in Stockholm (APSIS). Eur Heart J 1996;17:76-81.
21. Gong L, Zhang W, Zhu Y, et al: Shanghai Trial of Nifedipine in the Elderly (STONE). J Hypertens 1996; 14:1237-1245.
22. Messerli FH, Boden WE, Fischer Hansen J, Schechtman KB: Heart rate lowering calcium antagonists (HRL-CA) in hypertensive post M1 patients (abst). J Am Coll Cardiol 1996;27(2):178A.
23. Davis BR, Cutler JA, Gordon DJ, et al, for the ALLHAT: Rationale and Design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens 1996;9:342-360.
24. Hansson L, Zanchetti A, HOT Study Group: The Hypertension Optimal Treatment (HOT) Study: patient characteristics: randomization, risk profiles, and early blood pressure results. Blood Pressure 1994;3:322-327.